Advanced in Metastatic Pleural Tumor

Luigi Cavanna

Piacenza, IT 
Advanced in Metastatic Pleural Tumor
Piacenza, IT 
OverviewLocationsClinical Research

Overview

Luigi Cavanna practices in Piacenza, Italy. Mr. Cavanna is rated as an Advanced expert by MediFind in the treatment of Metastatic Pleural Tumor. His top areas of expertise are HER-2 Positive Breast Cancer, Breast Cancer, Metastatic Pleural Tumor, Bone Marrow Transplant, and Mastectomy.

His clinical research consists of co-authoring 174 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Metastatic Pleural Tumor.

Gender
Male

Locations

Piacenza, Italy
Other Locations
Casa Di Cura, Italy
Genoa, Italy
Bologna, Italy
Arcispedale S. Maria Nuova IRCCS
Reggio Nell'emilia, Italy
Avellino, Italy
Modena, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2)
Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2)
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drugs: Trastuzumab, Pertuzumab
Study Phase: Phase 2
Group Sequential Response Adaptive Randomized Clinical Trial of Concomitant Chemotherapy Plus Endocrine Therapy Versus Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitor Plus Endocrine Therapy for Advanced Hormone Receptor-positive, HER2-negative Breast Cancer.
Group Sequential Response Adaptive Randomized Clinical Trial of Concomitant Chemotherapy Plus Endocrine Therapy Versus Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitor Plus Endocrine Therapy for Advanced Hormone Receptor-positive, HER2-negative Breast Cancer.
Enrollment Status: Completed
Publish Date: November 07, 2024
Intervention Type: Drug
Study Drugs: Concomitant Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitor plus Endocrine Therapy, Chemotherapy plus Endocrine Therapy
Study Phase: Phase 2
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2023
Intervention Type: Drug
Study Drugs: Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs
Study Phase: Phase 2
An Open-label, Randomized Phase III Study of Early Switch Maintenance vs DElayed Second-line Nivolumab in Advanced Stage Squamous Non Small-cell Lung Cancer (NSCLC) Patients After Standard First-line Platinum-based Chemotherapy - EDEN Trial
An Open-label, Randomized Phase III Study of Early Switch Maintenance vs DElayed Second-line Nivolumab in Advanced Stage Squamous Non Small-cell Lung Cancer (NSCLC) Patients After Standard First-line Platinum-based Chemotherapy - EDEN Trial
Enrollment Status: Unknown
Publish Date: October 03, 2022
Intervention Type: Other, Drug
Study Drug: Nivolumab
Study Phase: Phase 3
Phase II, Open Label, Randomized, Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Subcutaneous (SC) Trastuzumab in Patients With Operable or Locally Advanced/Inflammatory HER2-positive Breast Cancer (ImmunHER)
Phase II, Open Label, Randomized, Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Subcutaneous (SC) Trastuzumab in Patients With Operable or Locally Advanced/Inflammatory HER2-positive Breast Cancer (ImmunHER)
Enrollment Status: Unknown
Publish Date: October 14, 2020
Intervention Type: Biological, Drug
Study Drugs: Trastuzumab, Pertuzumab, Docetaxel
Study Phase: Phase 2
A Standard Regimen of Dexamethasone in Comparison to Two Dex-sparing Regimens in Addition to NEPA in Preventing CINV in naïve NSCLC Patients to be Treated With Cisplatin Based Chemotherapy: a Three-arm, Open-label, Randomized Study
A Standard Regimen of Dexamethasone in Comparison to Two Dex-sparing Regimens in Addition to NEPA in Preventing CINV in naïve NSCLC Patients to be Treated With Cisplatin Based Chemotherapy: a Three-arm, Open-label, Randomized Study
Enrollment Status: Unknown
Publish Date: April 03, 2020
Intervention Type: Drug
Study Drugs: Netupitant+Palonosetron, Dexamethasone
Study Phase: Phase 3
A Phase II Randomized Trial Comparing a Combination of Abraxane and Gemcitabine Versus Gemcitabine Alone as First Line Treatment in Locally Advanced Unresectable Pancreatic Cancer. GAP (Gemcitabine Abraxane Pancreas) Trial
A Phase II Randomized Trial Comparing a Combination of Abraxane and Gemcitabine Versus Gemcitabine Alone as First Line Treatment in Locally Advanced Unresectable Pancreatic Cancer. GAP (Gemcitabine Abraxane Pancreas) Trial
Enrollment Status: Completed
Publish Date: October 09, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase III Study Of Low-Docetaxel Oxaliplatin, Capecitabine (Low-Tox) Vs Epirubicin, Oxaliplatin And Capecitabine (Eox) In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
A Randomized Phase III Study Of Low-Docetaxel Oxaliplatin, Capecitabine (Low-Tox) Vs Epirubicin, Oxaliplatin And Capecitabine (Eox) In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
Enrollment Status: Terminated
Publish Date: October 09, 2019
Intervention Type: Drug
Study Phase: Phase 3
Maintenance Metronomic Per OS Navelbine In Advanced NSCLC Patients After Previous Platinum Based Chemotherapy: A Multicenter Randomized Best Supportive Care Controlled Phase II Study - MA.NI.LA. Trial
Maintenance Metronomic Per OS Navelbine In Advanced NSCLC Patients After Previous Platinum Based Chemotherapy: A Multicenter Randomized Best Supportive Care Controlled Phase II Study - MA.NI.LA. Trial
Enrollment Status: Completed
Publish Date: April 22, 2019
Intervention Type: Drug
Study Phase: Phase 2
Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression
Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression
Enrollment Status: Terminated
Publish Date: January 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

173 Total Publications

Quality of life among retired oncologists and their willingness to serve: a nationwide representative survey.
Quality of life among retired oncologists and their willingness to serve: a nationwide representative survey.
Journal: Recenti progressi in medicina
Published: August 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cavanna's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 31 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile